购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Others
    (1)
TargetMol | Tags 通过 货期 筛选
  • 1-2周
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "infigratinib mesylate"的结果
筛选
搜索结果
TargetMol产品目录中 "

infigratinib mesylate

"的结果
  • 抑制剂&激动剂
    1
    TargetMol | Inhibitors_Agonists
  • Infigratinib mesylate
    T710031310746-12-3
    Infigratinib mesylate, also known as, BGJ398 mesylate or NVP-BGJ398 mesylate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib mesylate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.
    • ¥ 10600
    1-2周
    规格
    数量
  • Infigratinib phosphate
    磷酸英非替尼, NVP-BGJ398 phosphate, BGJ-398 phosphate
    T163641310746-10-1
    Infigratinib phosphate (BGJ-398 phosphate) 是 FGFR 抑制剂,对 FGFR1,FGFR2 和 FGFR3 的 IC50 分别为0.9,1.4 和 1 nM,比对 FGFR4 和 VEGFR2 的抑制性高40倍,对 Abl,Fyn,Kit,Lck 和 Lyn 几乎无活性。
    • ¥ 185
    In stock
    规格
    数量
  • Infigratinib acetate
    T710021310746-17-8
    Infigratinib acetate, also known as, BGJ398 acetate or NVP-BGJ398 acetate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib acetate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.
    • ¥ 10600
    1-2周
    规格
    数量
  • Infigratinib monohydrate
    T710041310746-11-2
    Infigratinib monohydrate, also known as, BGJ398 monohydrate or NVP-BGJ398 monohydrate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib monohydrate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.
    • ¥ 10600
    1-2周
    规格
    数量
  • Infigratinib
    NVP-BGJ398, BGJ-398
    T1975872511-34-7
    Infigratinib (NVP-BGJ398) 是一种 FGFR 家族抑制剂,抑制 FGFR1,FGFR2,FGFR3和 FGFR4的 IC50分别为 0.9 nM,1.4 nM,1 nM,60 nM。
    • ¥ 185
    In stock
    规格
    数量